Truist analyst Richard Newitter raised the firm’s price target on Teleflex to $270 from $221 and keeps a Hold rating on the shares as part of a broader research note, turning more positive on the MedTech industry heading into FY24. The firm is citing dwindling recession fears, a downward interest rate bias/perception, a “more pragmatic” view toward the GLP1 overhang/impact, and an attractive sector growth profile for MedTech next year. After a “tough” 2023 in healthcare, MedTech could be a relative destination for funds within healthcare and even “inter-sector” as a “beta/growth” segment that underperformed, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TFX:
- Teleflex price target raised to $265 from $225 at Wells Fargo
- These 2 MedTech Stocks Look Too Cheap to Ignore, Says Morgan Stanley
- Teleflex Awarded Peripheral Access Agreement with Premier, Inc.
- Teleflex awarded peripheral access agreement with Premier
- Teleflex upgraded to Overweight at Morgan Stanley on Palette upside, strong core